A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults

← catalyst calendar

NCT07594769 · readout in 12 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Other

Enrollment

36estimated

Sites

Country

Belgium

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-05-08

actual

When the study began enrolling

Primary completion

2026-08-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-08-31

estimated

The whole study's end, after follow-up

First posted

2026-05-19

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-10

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Migraine

Interventions

Drug: ODT2 Test formulation
Drug: ODT Reference formulation

Primary outcomes

what the primary-completion date above is the date OF

Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUCinf) of the test and reference formulations

measured Pre-dose to 72 hours

Area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUClast) of the test and reference formulations

measured Pre-dose to 72 hours

Maximum observed plasma concentration (Cmax) of test and reference formulations

measured Pre-dose to 72 hours

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed